ReviewJournal of neurology2025
The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review.
Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of low-dose rituximab in MuSK antibody-positive myasthenia gravis: a single-center retrospective study.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating muscle weakness due to antibody-mediated impairment of acetylcholine receptor (AChR) function. Traditionally, MG has been regarded as a disease primarily affecting skeletal muscles, and most research has focused on its motor manifestations. However, increasing evidence suggests that MG is a systemic disorder that can also present with a wide range of non-motor symptoms, which may significantly affect both quality of life and disease outcomes. This review provides a comprehensive overview of the non-motor manifestations of MG, including autonomic, cognitive, psychiatric, sensory, and gastrointestinal disturbances, as well as cardiovascular and sleep abnormalities. We discuss the underlying pathophysiological mechanisms that may explain these symptoms, focusing on immune dysregulation, autonomic imbalance, and potential antibody cross-reactivity with nicotinic acetylcholine receptor subtypes in non-skeletal tissues. Moreover, diagnostic and therapeutic implications are addressed, emphasizing the need for multidisciplinary management to adequately assess and treat these often-overlooked aspects of the disease. Although current evidence remains limited, mainly derived from small cohorts or case reports, the recognition of non-motor symptoms in MG represents an essential step toward a more holistic understanding of the disease. Future research should aim to elucidate their prevalence, underlying mechanisms, and treatment strategies through well-designed, prospective studies. Overall, this review highlights the importance of incorporating the assessment of non-motor manifestations into routine MG care to improve patient outcomes and quality of life.
Indexed as
Identifiers
41243030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.